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RADIATION ONCOLOGY PHYSICS

Tuning of AcurosXB source size setting for small intracranial
targets
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Abstract
This study details a method to evaluate the source size selection for small ﬁeld intracranial
stereotactic radiosurgery (SRS) deliveries in Eclipse treatment planning system (TPS) for
AcurosXB dose calculation algorithm. Our method uses end-to-end dosimetric data to
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evaluate a total of ﬁve source size selections (0.50 mm, 0.75 mm, 1.00 mm, 1.25 mm,
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Varian Medical Systems

deﬁnition MLC) and two delivery types for intracranial SRS (volumetric modulated arc

and 1.50 mm). The dosimetric leaf gap (DLG) was varied in this analysis (three DLG values
were tested for each scenario). We also tested two MLC leaf designs (standard and hightherapy [VMAT] and dynamic conformal arc [DCA]). Thus, a total of 10 VMAT plans and
10 DCA plans were tested for each machine type (TrueBeam [standard MLC] and Edge
[high-deﬁnition MLC]). Each plan was mapped to a solid water phantom and dose was calculated with each iteration of source size and DLG value (15 total dose calculations for
each plan). To measure the dose, Gafchromic ﬁlm was placed in the coronal plane of the
solid water phantom at isocenter. The phantom was localized via on-board CBCT and the
plans were delivered at planned gantry, collimator, and couch angles. The planned and
measured ﬁlm dose was compared using Gamma (3.0%, 0.3 mm) criteria. The vendorrecommended 1.00 mm source size was suitable for TrueBeam planning (both VMAT
and DCA planning) and Edge DCA planning. However, for Edge VMAT planning, the
0.50 mm source size yielded the highest passing rates. The difference in dose calculation
among the source size variations manifested primarily in two regions of the dose
calculation: (1) the shoulder of the high-dose region, and (2) for small targets (volume
≤ 0.30 cc), in the central portion of the high-dose region. Selection of a larger than optimal source size can result in increased blurring of the shoulder for all target volume sizes
tested, and can result in central axis dose discrepancies in excess of 10% for target volumes sizes ≤ 0.30 cc. Our results indicate a need for evaluation of the source size when
AcurosXB is used to model intracranial SRS delivery, and our methods represent a feasible
process for many clinics to perform tuning of the AcurosXB source size parameter.
PACS
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1 | INTRODUCTION
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machine types with different MLC models: (1) Varian Edge machine
(SN: 2003), which was installed in 2014 with Millennium120 HD-

Stereotactic radiosurgery (SRS) has become a valuable treatment
1

2

MLC (central bank MLC leaf width 0.25 cm), and (2) Varian True-

modality to treat lesions within the brain and spine. In particular,

Beam machine (SN: 2440), which was installed in late 2015 with

SRS provides a non-invasive treatment approach for unresectable

standard Millennium120 MLC (central bank MLC width 0.5 cm). For

tumors (such as those in the eloquent cortex or otherwise deep-

each machine, plans were generated for two delivery modalities (dy-

seated tumors) or for patients who are otherwise not candidates for

namic conformal arc [DCA] and volumetric modulated arc therapy

3

[VMAT]). Thus, for each machine type, the analysis included 10 DCA

surgery.

Though SRS was ﬁrst performed using a specialized device, now

plans and 10 VMAT plans. The two different delivery modalities

commercially available as the GammaKnife, technological advances

were selected to highlight potential differences between intensity-

have allowed for stereotactic therapies using the linear accelerator.

modulated deliveries (VMAT) and deliveries similar to MLC-deﬁned

Several noteworthy advances have allowed for improved precision in

open ﬁelds (DCA).

linear accelerator-based SRS: (1) the advent of treatment room

All planning and dose calculations were performed using Varian

stereotactic imaging systems,4–7 including stereoscopic planar imag-

Eclipse (v. 13) TPS and AcurosXB dose calculation algorithm (v. 13;

ing and cone-beam CT imaging, (2) improvements in patient support

1.0 mm isotropic dose calculation grid size and dose to medium cal-

devices, including 6 degree-of-freedom capabilities in the treatment

culation setting). The dose to medium setting was used in accor-

couch8 and improvements in couch movement precision, (3) increas-

dance with recently published recommendations from the NRG

ing availability of high-intensity photon modes,9–11 such as ﬂatten-

physics group.22 The current study was designed to evaluate the

ing-ﬁlter free photon modes with dose rates up to 2400 MU/min,

source size setting for small intracranial targets, with target volumes

(4) high-deﬁnition multi-leaf collimator (MLC) systems with leaf

as small as 0.03 cc (which corresponds to approximately 4 mm diam-

12,13

widths as narrow as 2.5 mm,

and (5) optical monitoring systems

to track patient motion throughout the treatment course.14,15

eter); in addition, several other studies have used smaller dose grid
size (i.e., less than 1.5 mm) as the standard for dose calculation com-

Of course, the advances in the preceding paragraph all focus on

parisons when evaluating small-ﬁeld dosimetry.23–26 With this in

the treatment delivery, while an accurate end-to-end treatment

mind, this study used 1.0 mm dose grid size for all dose calculations.

delivery relies on the marriage of the dose modeling within the

All planning was done with 6x-FFF beam energy with nominal dose

treatment planning system and the physical dose delivery within the

rate set to the maximum setting (1400 MU/min). The patient treat-

treatment room. Along these lines, the modeling of small-ﬁeld dose

ment plan was generated with beam model parameters following the

delivery has garnered much interest. The accurate measurement and

vendor recommendations for source size (spot size setting of

modeling of small-ﬁeld dose delivery (i.e., ﬁeld sizes < 3 9 3 cm in

1.00 mm in X- and Y-directions) and our current clinical values for

water-equivalent media) has many challenges, including the effects

MLC parameters (i.e., dosimetric leaf gap (DLG) and MLC leaf trans-

of the ﬁnite size of the radiation source, loss of charged particle

mission value).7 The details of the relevant treatment planning data

equilibrium (CPE), and sensitivity to small changes in ﬁeld size for

(including target volume size and location) are shown in Table 1 for

2

perturbation factors of ion chambers used for measurement.

16

The

Edge linac and Table 2 for TrueBeam linac.

AcurosXB algorithm gives a discretized solution to the linear Boltz-

To study the inﬂuence of source size on the calculated dose for

mann transport equation,17–19 which provides improvements in

cranial SRS deliveries, a total of 5 AcurosXB beam models were cre-

regions with loss of CPE, such as heterogeneity interfaces.20,21 How-

ated for each machine type. The user can tune the source size in the

ever, the proper selection of source size within the AcurosXB algo-

beam conﬁguration module through varying the effective target spot

rithm is still essential for the accurate modeling of small ﬁeld

size value, which is entered by the user separately for X- and Y-

deliveries. The purpose of this study was two-fold: (1) to present a

directions.19 All beam models used the same input measured data

clinically achievable method to evaluate the source size for small-

(percent depth-dose, cross-line proﬁles, and output factors), with the

ﬁeld dose calculation, and (2) to use the method to evaluate the

source size varied from 0.50 mm to 1.50 mm in 0.25 mm increments

ideal source size setting within AcurosXB for ﬂattening-ﬁlter energy

for each machine type. Each beam model was then calculated sepa-

modes for two delivery platforms (Varian Edge and TrueBeam machi-

rately with its unique source size value. In addition to the source size

nes), MLC leaf models (Millennium120 HD-MLC and standard Mil-

parameter, the DLG was also varied in the analysis. In Eclipse, the

lennium120 MLC), and delivery techniques for intra-cranial SRS

DLG represents the TPS method for modeling of the rounded MLC

planning (DCA and VMAT).

leaf end.19 For small MLC-deﬁned ﬁelds, the leaf end modeling and
the potentially partial viewing of the ﬁnite size of the radiation

2 | METHODS

source along the central axis are inherently coupled. The DLG
parameter is not included within the Beam Conﬁguration workspace

2.A | Treatment planning and beam modeling

in ARIA v. 13; rather, it is included in the machine properties of the

A total of 40 cranial SRS plans were generated for analysis in this

also varied in our analysis: three DLG values were included in the

IRB-approved retrospective study. The analysis included two

modeling and calculation analysis for each machine type.

RT Administration workspace. Nonetheless, the DLG parameter was
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T A B L E 1 Relevant treatment planning data for (a) DCA and
(b) VMAT planning for Edge linac.

Patient number

Disease site

PTV
volume
(cc)

Rx dose
(Gy)

Max ﬁlm
plane dose
(Gy)

T A B L E 2 Relevant treatment planning data for (a) DCA and
(b) VMAT planning for TrueBeam linac.
Patient
number

Disease
site

PTV
volume
(cc)

Rx dose
(Gy)

Max ﬁlm
plane
dose (Gy)

(a) Varian truebeam – DCA planning

(a) Varian edge – DCA planning
1

Lt frontal

0.04

18

13.67

1

Rt temporal

2.01

18

14.66

2

Rt ant frontal

0.07

18

12.65

2

Rt parietal

0.85

18

12.17

3

Lt frontal

0.03

20

14.7

3

Rt frontal

0.82

18

12.07

4

Lt frontal

0.23

18

15.69

4

Lt cerebeller

1.01

18

15.12

5

Rt parietal

0.04

18

14.65

5

Rt parietal

1.93

18

14.13

6

Lt inf frontal

1.29

18

14.49

6

Rt cerebeller

1.64

18

15.9

7

Lt temporal

0.33

18

13.01

7

Rt thalamus

0.69

18

17.65

8

Cerebellar

0.48

18

18.55

8

Lt frontal

0.46

18

13.78

9

Rt frontal

0.32

18

14.48

9

Lt cerebeller

0.49

18

19.97

10

Rt parietal

0.19

18

14.45

10

Lt frontal

0.38

18

12.03

(b) Varian truebeam – VMAT planning

(b) Varian edge – VMAT planning
1

Rt parietal

0.31

20

14.47

1

Lt parietal

0.67

18

15.96

2

Rt ant frontal

0.07

18

16.63

2

Rt precentral

0.78

18

15.88

3

Rt temporal

0.39

18

16.23

3

Resection cavity SRS

15

13.99

4

Rt CPA

0.86

16

16.43

4

Rt acoustic neuroma

13

14.13

5

Lt frontal

0.03

20

17.92

5

Rt parietal

1.22

18

16.97

6

Lt frontal

0.23

18

16.16

6

Lt temporal

0.24

18

16.84

7

Lt temporal

1.29

18

15.6

7

Lt inf frontal

0.33

18

18.29

8

Lt inf frontal

0.33

18

17.21

8

Lt temporal

1.29

18

14.94

9

Rt acoustic

0.75

13

12.36

9

Lt acoustic

1.16

12

11.34

Lt brainstem

0.51

9

10.64

10

Rt frontal

2.07

18

16.62

10
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13.9
0.43

All treatment plans were mapped to a water-equivalent slab

available to the radiation oncology community, making our methods

phantom, with total phantom dimensions of 15 cm 9 30 cm 9 30 cm

described here feasible for many clinics. The ﬁlms were handled

(Gammex Inc., Middleton, WI, USA). The isocenter was placed in the

according to the recommendations of AAPM Task Group 55.27 The

center of the phantom, corresponding to 7.5 cm depth. Each treat-

phantom localization and treatment procedure followed our clinical

ment plan was calculated for all combinations of source size beam

process for intracranial SRS treatment delivery. Speciﬁcally, the

model and DLG value. Thus, for each treatment plan, a total of 15 dose

phantom and ﬁlm plane (coronal plane at mid-phantom – 7.5 cm

calculations were performed to sample the various source size and

depth) were localized using CBCT imaging prior to dose delivery

DLG values for dose calculation. All dose calculations were performed

(125 kVp, Full-fan ﬁlter, 1 mm slice thickness), and all plans were

with the same monitor unit values determined during the original plan

delivered at planned gantry, collimator, and couch angles. The aver-

optimization. After dose calculation was completed, planar dose

age delay time between irradiation and ﬁlm scanning was approxi-

planes were exported for analysis (512 9 512 matrix resolution,

mately 24 hr. Films were scanned in an Epson Expression 10000XL

5 cm 9 5 cm matrix size).

ﬂatbed scanner (Seiko Epson Corp, Nagano, Japan). All ﬁlms were
scanned at the center of the scanner bed with resolution settings of

2.B. | Gafchromic ﬁlm measurements and
calibration

150 dot per inch and 48 bit RGB mode (16 bits per color channel). A

Film measurements using Gafchromic EBT3 ﬁlm (Film Size:

via green channel due to its superior sensitivity at the dose levels

20.3 9 25.4 cm2; Ashland Inc., Covington, KY, USA) were used to

larger than 10 Gy.28

four-way ﬂip method was used to average out any intrinsic light
source non-uniformity of the scanner. Dosimetric analysis was done

evaluate the dose calculation accuracy in this study. Gafchromic ﬁlm

The ﬁlm calibration and dosimetric analysis was performed using

was selected due to several attractive detector properties: extremely

in-house software. Calibration ﬁlms were irradiated in a nine square

high spatial resolution, large planar detection area, minimal direc-

dose pattern (area of 2 9 2 cm2 per square). The in-house calibra-

tional dependence, and low energy dependence. In addition, Gaf-

tion routine matches the ﬁlm optical densities within each square to

chromic ﬁlm and associated dosimetric analysis tools are widely

the TPS calculated dose for the same beam geometry. Then, a

GARDNER
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calibration curve was generated using cubic polynomial least squares

1 mm is quite large relative to the lesion radius (for example, the

ﬁtting.

radius of a 0.5 cc spherical lesion is approximately 5 mm). See Fig. 1
for comparison of the Gamma criteria for one of the representative
cases. The value for dose threshold was set to 20% of the maximum

2.C. | Dose distribution analysis

ﬁlm plane dose, which corresponds to roughly 25% of the prescrip-

The ﬁlm measurements were compared to the calculated dose planes

tion dose for these cases.

using Gamma analysis.29 Typical Gamma analysis for patient-speciﬁc
IMRT QA may use distance-to-agreement criteria of 2–3 mm. However, the measurement scale (percentage of measurement points

2.D. | Statistics

with passing Gamma values) is often saturated if typical Gamma cri-

Gamma analysis passing rate results for each source size setting

teria are used. To determine the appropriate Gamma analysis criteria

were compared to passing rate results for vendor-recommended

for this study, the Gamma analysis passing rate results for two repre-

source size setting using Student’s t-test, assuming two-tailed distri-

sentative cases were logged for a variety of dose difference and dis-

bution with P < 0.05 signiﬁcant.

tance-to-agreement criteria and compared to qualitative visual dose
proﬁle analysis. The best agreement between passing rate result and
visual proﬁle analysis was found for the following Gamma criteria:
3% dose difference and 0.3 mm distance-to-agreement. It should be
noted that these criteria are likely too strict for planning with con-

3 | RESULTS
3.A. | Film dosimetry results – gamma analysis

ventional target sizes. But, for very small targets such as those found

The Gamma analysis passing rate results for Edge linac are shown in

in intracranial SRS planning, a distance-to-agreement criteria of

Fig. 2 (VMAT Planning) and Fig. 3 (DCA Planning). For each plot, the

(h)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

F I G . 1 . Comparison of Gamma analysis criteria for one representative case from the study. The red regions in each Gamma map represent
failing pixels for the relevant Gamma criteria used. a, Planned dose (1.50 mm source size) plane with line proﬁle geometry (green horizontal
line). b, Green channel ﬁlm dose plane. c, Gamma map for 1%,1 mm criteria. d, Gamma map for 2%, 1 mm criteria. e, Gamma map for 3%,
1 mm criteria. f, Gamma map for 3%, 0.5 mm criteria. g, Gamma map for 3%, 0.3 mm criteria. h, Line proﬁle comparing the AcurosXB planned
dose (1.50 mm source size) and green channel ﬁlm dose. Note the disagreement between planned and measured dose in the shoulder of the
high-dose region. Gamma analysis using 1 mm dose-to-agreement criteria is insensitive to such discrepancy in the dose distribution, while
Gamma analysis with tighter distance-to-agreement criteria (e.g., 0.3 or 0.5 mm) shows failing points in the shoulder of the high-dose region
that match observed dose distribution discrepancies. The Gamma analysis criteria used for this study: 3%, 0.3 mm.
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F I G . 2 . Gamma passing rate results for VMAT planning with Edge linac (HD-MLC). Note that the highest passing rates occur for the
0.090 cm DLG setting, and the optimal source size varies with DLG setting. For DLG value of 0.090 cm, the 0.50 mm source size results in
the highest passing rate (mean  SD passing rate of 97.51  2.38%). The vendor-recommended source size setting (1.00 mm) with the same
DLG value (0.090 cm) yields a lower mean passing rate result with larger variation–mean  SD passing rate 93.72  4.96%.

F I G . 3 . Gamma passing rate results for DCA planning with Edge linac (HD-MLC). The optimal source size for these data is 1.00 mm for DLG
value 0.090 cm (corresponding to the optimal DLG value for VMAT planning). For DLG values of 0.070 cm and 0.080 cm, the highest passing
rates occurred for calculations with 0.75 mm source size setting.

whiskers indicate the maximum and minimum passing rates for each

as shown in Fig. 2 and exhibited by the passing rate results

source size setting and DLG value. The ﬁrst, second, and third quartile

(mean  SD): 96.36  4.41% (0.50 mm, P = 0.04), 98.71  2.21%
P = 0.17),

89.96  7.17%

values for each combination of settings are also displayed on the plot.

(0.75 mm,

Of the DLG settings tested for VMAT delivery with Edge linac, the

81.79  8.30% (1.50 mm, P < 0.001).

(1.25 mm,

P < 0.01),

best overall agreement between measured and planned dose occurred

The Gamma analysis passing rate results for TrueBeam linac are

for DLG value of 0.090 cm. For 0.090 cm DLG value, the 0.50 mm

shown in Fig. 4 (VMAT Planning) and Fig. 5 (DCA Planning). Of the

source size setting yielded the highest passing rate (mean  SD):

DLG settings tested for VMAT delivery with TrueBeam linac, the

97.51  2.38% (P = 0.01). The passing rates (mean  SD) for the

best agreement between measured and planned dose occurred for

other source sizes were as follows: 96.25  3.51% (0.75 mm,

DLG value of 0.180 cm. For this DLG value, the 1.00 mm source

P < 0.01), 93.72  4.96% (1.00 mm), 84.97  6.93% (1.25 mm,

size setting yielded the highest average passing rate (mean  SD):

P < 0.001), and 78.83  7.10% (1.50 mm, P < 0.001).

97.98  3.06%. The passing rate for the remaining source sizes with

For DCA planning with DLG value of 0.090 cm, the highest pass-

0.180 cm DLG value were as follows: 95.02  4.68% (0.50 mm,

ing rate occurred for vendor-recommended source size of 1.00 mm

P < 0.01), 97.22  3.76% (0.75 mm, P = 0.066), 95.91  4.33%

(mean  SD): 99.41  0.99%. We note a sharper decline in passing

(1.25 mm, P = 0.067), 92.46  5.88% (1.50 mm, P < 0.01).

rate for larger-than-optimal source sizes (1.25 mm and 1.50 mm)

For DCA planning with TrueBeam linac and DLG value of

than for smaller-than-optimal source sizes (0.50 mm and 0.75 mm)

0.180 cm, the highest mean passing rate occurred for source sizes

GARDNER
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F I G . 4 . Gamma passing rate results for VMAT planning with TrueBeam linac (Millennium-120 MLC). Note that the highest passing rates
occur for the 0.180 cm DLG setting, and the optimal source size varies with DLG setting. For DLG value of 0.180 cm, the 1.00 mm source
size yields the highest passing rates (mean  SD): 97.84  3.66%. For lower DLG value (0.160 cm), the average passing rate results for
0.50 mm, 0.75 mm and 1.00 mm settings were within 0.7% of one another. The highest passing rate for DLG value 0.160 cm occurred for
smaller source size – 0.75 mm setting with meanSD passing rate of 96.16  5.83%. For the larger DLG value (0.200 cm), the highest average
passing rate occurred for larger source size – 1.25 mm setting with mean  SD passing rate of 93.65  6.19%.

F I G . 5 . Gamma passing rate results for DCA planning with TrueBeam linac (Millennium-120 MLC). For 0.180 cm DLG value, the highest
passing rates occurred for source sizes of 1.00 mm (99.16  2.47%) and 1.25 mm (99.45  0.99%).

of 1.00 mm (99.16  2.47%) and 1.25 mm (99.45  0.99%), with

measured and calculated dose for multiple VMAT plans (one smaller

no statistical signiﬁcance in the difference in passing rate for these

target size and one typical intracranial SRS target size) for Edge and

two source sizes (P = 0.62). For all but one TrueBeam DCA case, the

TrueBeam linacs is shown in Fig. 6. For Edge linac and smaller target

1.00 mm and 1.25 mm source size dose calculations yielded passing

volume (0.07 cc) shown in Fig. 6 (a) we note two main differences in

rates in excess of 99.50%. The mean  SD passing rate for the

the high-dose region among the source size calculations. First, there

remaining source sizes were as follows: 96.95  5.23% (0.50 mm,

is an increase in the blurring of the shoulder of the high-dose region

P = 0.04), 98.62  3.63% (0.75 mm, P = 0.17), and 97.94  2.35%

as the source size is increased. In addition, there is a reduction in the

(1.50 mm, P = 0.26).

magnitude of the central high-dose region as the source size is
increased. For this case, the 0.75 mm source size calculation yields

3.B. | Film dosimetry results – dose proﬁle
comparison

the best agreement with the measured dose. In the low dose region

To highlight the variations in dose calculation with source size setting,

Similar behavior within the high-dose region for VMAT planning with

line proﬁle comparisons were also generated for several representa-

TrueBeam linac and smaller target volume (0.24 cc) is shown in Fig. 6

tive VMAT cases for Edge and TrueBeam linacs. A comparison of

(c). For this case, the 1.00 mm source size calculation gives the best

(< 40% of peak dose) for this case, there is also some difference in
dose calculation among the calculations with various source sizes.
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F I G . 6 . Comparison of measured dose (red solid line) with calculated dose for the source size settings tested for VMAT planning with Edge
and TrueBeam linacs. All calculations performed using optimal DLG value: 0.090 cm for Edge linac and 0.180 cm for TrueBeam linac. a, VMAT
planning for a small volume target (0.07 cc) with Edge linac. As the source size increases, the magnitude of the central high-dose region is
dramatically reduced (indicated by black arrow), the shoulder of the high-dose region exhibits blurring (light gray arrow), and the low dose region
also exhibits differences as a function of source size (gray arrow). b, VMAT planning for a typical volume target (0.86 cc) with Edge linac. Note
the similar blurring of the shoulder of the high-dose region (black arrow), but no difference in the magnitude of the central high-dose region. c,
VMAT planning for a smaller volume target (0.24 cc) for TrueBeam linac. Note the similar behavior in the central region, shoulder of the highdose region, and low dose region to proﬁle comparison in (a). d, VMAT planning for a typical volume target (0.67 cc). Again, there remains
characteristic blurring of the shoulder of the high-dose region without variation in the magnitude of the central high-dose region.
agreement with measurement. For more typical intracranial lesions

popular option for the delivery of stereotactic radiosurgery for

with target volumes in the range of 0.5–1.0 cc (shown in Figs. 6 (b)

treatment of small intracranial lesions. Recently, advances in linac

and 6 (d)), we note the same blurring of the shoulder of the high-dose

design have included incorporation of stereotactic on-board imag-

region, without the dramatic reduction in the magnitude of the cen-

ing systems,4–7 high-deﬁnition MLC,12,13 integrated 6 DOF couch,8

tral high-dose region. For the larger volume case shown in Fig. 6 (b)

high-intensity ﬂattening ﬁlter free energy modes,9–11 and surface

for Edge linac, the 0.50 mm source size setting yields the best visual

imaging systems for tracking.14,15 With improvements in the local-

agreement between measured and calculated line proﬁles. For both

ization and delivery systems, there remains a deﬁnite need for

representative cases shown in Figs. 6 (c) and 6 (d) for TrueBeam linac,

accurate modeling of the small ﬁeld dose delivery within the treat-

the 1.00 mm source size setting yields the best visual agreement

ment planning system. The purpose of this study was two-fold: (1)

between measured and calculated line proﬁles.

to present a clinically achievable method to evaluate the source
size for small-ﬁeld dose calculation, and (2) to use the method to
evaluate the ideal source size for ﬂattening-ﬁlter energy modes for

4 | DISCUSSION

two delivery platforms (Varian Edge and TrueBeam machines),
MLC leaf models (Millennium120 HD-MLC and standard Millenni-

The modern linac, with capabilities for online image guidance and

um120 MLC), and delivery techniques (DCA and VMAT) used in

sub-millimeter end-to-end geometric accuracy, has become a

our clinic.
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Previous studies have provided validation of the AcurosXB dose

performance with a conventional linear accelerator (Varian Clinac

calculation algorithm for a variety of test cases. Vassiliev et al.com-

2100iX) with standard width MLC (Millennium-120) and standard

pared the AcurosXB dose calculation to Monte Carlo for 6 MV and

energy mode (6 MV). In this study, we evaluate various source size

18 MV beam energy in a heterogeneity slab phantom, ﬁnding that

settings in AcurosXB for dose calculations of small intra-cranial tar-

AcurosXB and Monte Carlo calculations agreed within 2% (local dose

gets for VMAT and DCA planning with two linear accelerator deliv-

difference) or 1 mm (distance to agreement).30 Stathakis et al. com-

ery platforms utilizing ﬂattening ﬁlter-free energy mode (6 MV-FFF).

pared small ﬁeld dose calculation within and beyond heterogeneities

For both AcurosXB and AAA, the Eclipse treatment planning sys-

for several commercially available dose calculation algorithms (includ-

tem utilizes a dual-source dose calculation model, consisting of the

ing AcurosXB) to Monte Carlo results, ﬁnding that AcurosXB agreed

primary source and extra-focal source.19 The extra-focal source is a

within 2% compared to Monte Carlo calculation in lung and bone

Gaussian plane source positioned at the edge of the ﬂattening ﬁlter

slab geometry.31 Kron et al. evaluated the accuracy of AcurosXB

distal to the target. For ﬂattening-ﬁlter free beams, such as the 6

dose calculation for situations with small MLC-deﬁned segments and

MV-FFF energy mode evaluated in this study, the extra-focal source

larger secondary collimation settings.24 Their study included testing

modeling is disabled, since the principal element contributing to the

the source size (focal spot size) for values of 0 mm, 1 mm, and

need for extra-focal modeling (i.e., the ﬂattening ﬁlter) is not present.

2 mm. They found agreement in output factor prediction between

The primary source can be tuned using the effective target spot size

AAA and AcurosXB to be within 1% for ﬁeld sizes ≥ 1 9 1 cm , and

parameter (entered separately for X- and Y- directions in the jaw

found acceptable agreement between planned and measured doses

coordinate system). The ﬁnite size of the primary source is modeled

for focal spot size settings of 1 mm or less, DLG value of 1.4 mm,

via Gaussian smoothing of the primary energy ﬂuence, with the spot

2

and MLC transmission value of 1.4%. Fogliata et al. evaluated the

size parameter representing the FWHM of the Gaussian ﬁlter in the

performance of AAA and AcurosXB for small MLC-deﬁned open

isocenter plane. The spot size parameter is coupled with the beam-

ﬁelds and VMAT deliveries.32 Their study evaluated 4 VMAT plans

limiting device (i.e., jaw or MLC). If the vendor-recommended spot

in total, but the plan details, including the arc geometry (single partial

size parameter (1.00 mm in X- and Y-directions) is used for Acur-

arc of 140°) and total dose per plan (2 Gy), are not fully representa-

osXB beam modeling, then the actual source size employed during

tive of typical intra-cranial SRS VMAT planning at our institution. In

dose calculation depends on the beam-limiting device: (1) if the ﬁeld

addition, the target volume range ([0.3 cc, 7.0 cc]) does not encom-

is delimited by jaws alone, then 1.00 mm is used for X- and Y-direc-

pass the target volume size that is typically treated at our institution.

tions, and (2) if MLC are used, then the following are used: 1.50 mm

In particular, our institution tends to utilize multiple arc delivery with

(X-direction) and 0 mm (Y-direction).19 In the current study, we note

typical prescription dosing (on the order of 18 Gy), and the volume

the difference in behavior for the two MLC models tested. For Mil-

of the targets at our institution can be less than 0.10 cc. Our study

lennium-120 MLC with 0.180 cm DLG value, the vendor-recom-

results indicate that the inﬂuence of the source size selection on the

mended 1.00 mm source size was suitable for both VMAT planning

dose calculation accuracy is of particular interest for target volume

DCA planning. For Millennium-120 HD-MLC, the 0.50 mm source

sizes less than approximately 0.30 cc. As shown in Fig. 7, use of

size setting yielded the highest passing rate results for VMAT plan-

source sizes larger than recommended (e.g., 1.25 mm and 1.50 mm

ning, while the was 1.00 mm source size yielded the highest passing

in this study) can result in further reduction in Gamma Analysis pass-

rate results for DCA planning. The differences in these results high-

ing rates for target volume sizes less than approximately 0.30 cc. In

light the need to perform machine- and treatment intent-speciﬁc

addition,

testing, particularly for small-ﬁeld delivery using VMAT. When

the

Fogliata

et al.

study

evaluated

F I G . 7 . Difference in Gamma Analysis
passing rate for each source size tested
relative to the vendor-recommended
source size (1.00 mm) for all cases tested
(all machine types and all delivery types).
Note the sharp decrease in passing rate for
smaller target volume size
(volume ≤ 0.30 cc) for source sizes larger
than the recommended 1.00 mm value
(1.25 mm and 1.50 mm).

the

algorithm
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selecting the optimal source size value for a clinical delivery system,

phantom just as they would in a clinical patient. We believe this

it is essential to understand the downside of using smaller source

avoids one major issue with typical IMRT QA, which is the lack of

size settings for AcurosXB (relative to the nominal recommended

correlation between per-beam planar measurements and clinically

source size). We note that our study ﬁndings indicate no statistically

meaningful dose errors. Third, our institutional ﬁlm analysis program

signiﬁcant difference in calculation time among the source sizes

allowed for the use of relatively small distance-to-agreement criteria

tested. However, choosing a source size setting that is too small

(on the order of 0.3 mm) for these cases; similar distance-to-agree-

could lead to overestimation of the size of the shoulder of the high-

ment criteria (0.5 mm) was previously used to validate GammaKnife

dose region. Thus, since the prescription isodose line is often in the

dosimetry.39 The details of our institutional practice for SRS/SBRT

shoulder of the high-dose region, this could lead to an overestima-

QA using Gafchromic ﬁlm have been published40; of note, the ﬁlm

tion of the prescription isodose cloud in the planning system. If a

analysis procedure includes a rigid registration routine using mutual

tradeoff is needed during commissioning and beam modeling, the

information as the similarity metric. For each case, the result of the

user should determine whether underestimating or overestimating

ﬁlm analysis image registration is reviewed. It should be noted that

the dose level of the shoulder of the high-dose region is preferable.

the use of such small distance-to-agreement criteria (0.3 mm) in the

For our clinic, there was signiﬁcant interest in using one beam model

gamma analysis was intended for use in this study and is not part of

for each machine. Namely, we looked to avoid using a separate

our institutional clinical routine; the use of such small distance-to-

beam model for VMAT and DCA deliveries. It is worth noting that

agreement relies on (1) robust image registration between the

there was no statistically signiﬁcant difference between the gamma

planned and measured dose planes, and (2) sufﬁciently ﬁne resolu-

analysis passing rates for 0.50 mm and 0.75 mm (P = 0.057) source

tion for both planned and measured dose planes. For this reason, we

size values for Edge VMAT delivery, and also no statistically signiﬁ-

used 1 mm isotropic dose grid setting (the lowest allowed in Eclipse

cant difference between the gamma analysis passing rates for

TPS), and exported all plans using 0.098 mm pixel size. Though not

0.75 mm and 1.00 mm (P = 0.175) source size values for Edge DCA

all gamma analysis criteria are sensitive to meaningful dose errors,

delivery. In addition, qualitative line proﬁle analysis indicated equiva-

we believe we have shown the 3% dose difference and 0.3 mm cri-

lent agreement between planned and measured dose for the

teria as employed in this study to be sensitive to meaningful dose

0.75 mm and 1.00 mm source size data for DCA delivery, as well as

errors in cranial SRS deliveries (see Fig. 1). However, we again stress

between the 0.50 mm and 0.75 mm source size data for VMAT

the usefulness of other complementary analysis tools, such as the

delivery. Thus, we evaluated all of our clinical goals, including: (1)

use of the gamma map and line proﬁle analysis, and caution against

avoid under coverage of the tumor due to overestimation of the pre-

the use of gamma passing rates alone in the commissioning or veriﬁ-

scription isodose cloud, (2) if at all possible, use a single beam model

cation process for SRS VMAT and DCA deliveries. The AAPM Task

for the Edge machine, and (3) use both quantitative gamma analysis

Group 119 introduced the concept of conﬁdence limits for determin-

and qualitative line proﬁle analysis. Taking all of these factors into

ing appropriate bounds of IMRT QA results.41 The formula used for

account, the 0.75 mm source size was chosen for our institutional

calculating

Edge beam model, which included use for both VMAT and DCA

Limit = ∣mean∣ + 1.96r Applying this formula to the VMAT ﬁlm

the

deliveries. Our study using Gafchromic EBT3 ﬁlm and solid water

dosimetry

slab phantom provides a feasible and effective method for evaluating

Size = 0.50 mm) yields a conﬁdence limit of 92.9% for lower bound

data

conﬁdence
for

(1)

limit

is

HD-MLC

as

follows:

Conﬁdence

(DLG = 0.090 cm,

Source

beam modeling parameters such as source size and DLG during

of passing rate, and (2) for Millennium-120 MLC (DLG = 0.180 cm,

machine commissioning.

Source Size = 1.00 mm) yields a conﬁdence limit of 90.7% for lower

The use of gamma analysis for IMRT QA has been the subject of

bound of passing rate. These conﬁdence limits are not generally

much scrutiny.33–38 In particular, gamma analysis using traditional cri-

applicable to all clinics, since they are based on a single institutional

teria for distance-to-agreement (on the order of 2–3 mm) and dose

QA dataset. Rather, these conﬁdence limits can be used as a qualita-

difference (on the order of 2–3%) may not be sensitive to clinically

tive reference when performing similar measurements for commis-

meaningful dose errors when per-beam IMRT analysis is used. We

sioning of small-ﬁeld VMAT deliveries.

note several considerations regarding the use of gamma analysis in

The dose proﬁle comparison indicated two important regions of

this study. First, gamma analysis provides a binary result for each

dose distribution variation resulting from tuning of the calculation

pixel (i.e., the pixel either passes or fails the test), and the gamma

model source size: the shoulder of the high-dose region and the cen-

analysis does not discriminate between delivered dose that is higher

ter of the high-dose region. First, we note differences in the shoul-

or lower than the planned dose. For this reason, commissioning of

der of the high-dose region (Fig. 6). As the source size increases, we

small-ﬁeld deliveries should not rely on gamma passing rates alone;

note the blurring of the shoulder of the high-dose region, which

rather, the gamma map and line proﬁle analysis should also be used

occurred for the entire range of target volume sizes tested. This

to give a better understanding of the agreement between planned

blurring is of particular importance for intracranial SRS planning,

and measured doses. In this study, we present gamma analysis pass-

since the prescription isodose line is typically in the shoulder region

ing rates and line proﬁle analyses of representative cases. Second, all

of the dose distribution to allow for sharp dose gradients outside

dose distributions analyzed in this study are composite dose distribu-

the target volume. Any discrepancy in the full width at 75–85% of

tions. The dose distributions for each arc are summed in the

the peak dose indicates that the planning system is not correctly

GARDNER

|

ET AL.

179

F I G . 8 . Comparison of isocenter dose
for Edge and TrueBeam linacs for VMAT
and DCA planning. Dose difference is the
isocenter dose 1.50 mm source size
relative to isocenter dose for optimal
VMAT source size (0.50 mm for Edge linac
and 1.00 mm for TrueBeam linac). The
blue dashed lines indicate region of target
volume less than 0.30 cc and dose
difference less than 3%. The black solid
lines indicate region with target volume
less than 0.15 cc and dose difference less
than 5%. The largest dose discrepancy was
10.80% for 0.03 cc volume target.

calculating the volume of the prescription isodose cloud. In addition,

proﬁle analyses) for the optimal source size and DLG value indicate

for very small targets (less than approximately 0.30 cc), the central

that the optimal beam model can give similar agreement between

portion of the high-dose region is also impacted by the source size

planned and measured doses for each MLC type. However, there

selection. As shown in Fig. 8, improper selection of the source size

exists a sharper decrease in passing rate for the Edge data for sub-

in the dose calculation model can result in meaningful reduction in

optimal selection of source size and DLG setting. It is worth noting

isocenter dose for lesions smaller than approximately 0.30 cc. For

the differences in lesion geometry for the two MLC types. For the

very small targets (lesions less than 0.10 cc), we note the presence

Edge linac, there were seven lesions (out of 20 total) below 0.30 cc,

of discrepancies in isocenter dose up to 10.8%. Of the lesions ana-

with only one such lesion for the TrueBeam linac. In addition, there

lyzed in this study with volume less than 0.10 cc, ﬁve of the six

were nine lesions above 1 cc for the TrueBeam linac, with only two

lesions had dose discrepancies in excess of 8%. These ﬁndings rein-

such lesions for the Edge linac. This was intentional, to ensure the

force the need to perform dosimetric veriﬁcation of the dose calcu-

lesion volumes were chosen to reﬂect the intended clinical use of

lation model at the smallest anticipated target volume size. If the

each MLC type. As has been shown in previous studies, the HD-

proper source size is not used in the dose calculation model, one

MLC is better able to deliver stereotactic treatments to small

potential mitigation strategy would include using a slightly larger

intracranial lesions as compared to standard width MLC.42 As shown

margin for intra-cranial lesions. Line proﬁle analysis in this study indi-

in Figs. 7 and 8, the dose calculation appears to be most sensitive to

cates that discrepancies between dose calculations with 0.5 mm and

variations in source size at the smallest lesion sizes (in this study, we

1.5 mm source size setting can routinely approach 1 mm in the

deem the lesion small if the volume is less than approx. 0.30 cc).

shoulder of the high-dose region. Though an explicit recommenda-

Under 0.30 cc, variations in source size lead to discrepancies in both

tion on lower bound for target size treated for each MLC type is

the shoulder and central area of the high-dose region. Thus, though

beyond the scope of this work, we have shown that proper tuning

our results indicate no statistically signiﬁcant difference in the agree-

of the source size and DLG parameters allow for reliable modeling

ment between planned and measured doses in this study for the

of the dose delivery with (1) HD-MLC to target volumes as small as

optimal Edge and TrueBeam beam models, any selection of subopti-

0.03 cc, and (2) Millennium-120 MLC to targets volumes as small as

mal source size (and also DLG value) has the potential to be more

0.24 cc. Other factors, such as the resolution of imaging systems

impactful, on average, for deliveries involving smaller lesions. In addi-

used for planning and localization (e.g., CT, MRI, and CBCT) and the

tion, our results indicate a difference in optimal source size for

lower bounds of the dose calculation grid size, also play a role in

VMAT delivery with these two MLC models, which we attribute to

determining the lower bound for target size.

the combination of differences in the MLC leaf end design and the

Of note, this study included analysis of conventional and high-

method by which the TPS models the ﬁnites size of the source (i.e.,

deﬁnition MLC models. We note several interesting differences in

a Gaussian convolution blurring). We believe that our study repre-

the passing rate trends for the Edge linac and TrueBeam linac among

sents the ﬁrst reporting of the differences in dose calculation as a

the entire set of source sizes tested. First, the optimal source size

function of source size with changes in MLC model for Eclipse TPS.

and DLG value resulted in similar mean passing rates for each deliv-

In addition, we note the difference in optimal source size as deter-

vs

mined using ﬁlm dosimetry for intensity-modulated delivery (VMAT)

DCA:

and open-ﬁeld delivery (DCA). Some previous studies have charac-

99.41  0.99% (Edge) vs 99.16  2.47% (TrueBeam; P = 0.77). We

terized the effects of source size using small MLC-deﬁned open

believe these similar passing rate results (and corresponding line

ﬁelds with beams at normal incidence and comparing to Monte Carlo

ery

modality:

97.84  3.66%

(1)

for

VMAT:

(TrueBeam;

97.51  2.38%

P = 0.81),

and

(2)

(Edge)
for
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calculations, ﬁlm dosimetry, or other high-resolution dosimetric
data.17,24,32 The difference in the ﬁlm dosimetry results in the current study for VMAT and DCA planning groups (particularly for Edge
linac with high-deﬁnition MLC) underscore the need to extend the
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deliveries.
The modeling of small-ﬁeld deliveries within Eclipse is a combination of the ﬁeld-speciﬁc output factor (determined from the collimator back scatter factor (CBSF) table in Eclipse), modeling of the MLC
leaf end (primarily determined from the DLG value in Eclipse), and
the modeling of the source. This study analysis included evaluation
of the latter two parameters, but did not fully consider the effects
of the CBSF table. However, all beam models were generated using
output factor down to jaw sizes of 1 9 1 cm2, with small ﬁeld data
measured using a stereotactic ﬁeld diode. It is important to note that
all plans analyzed in this study utilized jaw settings larger than
1 9 1 cm2;

the

smallest

jaw

setting

for

this

study

was

1.6 cm 9 1.4 cm (X by Y). Additionally, MLC-deﬁned small ﬁeld
delivery was validated for ﬁeld sizes down to 5 mm 9 5 mm using
multiple detectors. During commissioning, all small ﬁeld data was
measured multiple times and cross-compared to several detectors
for validation, and the calculated output factor data compared favorably with internal Monte Carlo testing. Thus, though we don’t explicitly consider the effects of the CBSF table in this study, all beam
models were generated with the appropriate selection of detector
and the data was validated in multiple ways. This study uses ﬁlm
dosimetry as the primary means to evaluate the accuracy of the
dose calculation model. In our clinic, we perform ﬁlm-based QA of
all intensity-modulated stereotactic deliveries. In general, the uncertainty in Gafchromic ﬁlm dosimetry arises from issues with ﬁlm uniformity, scanner uncertainties, background variations, ﬁlm handling,
and registration between ﬁlm and calculated dose planes. Our methods, including strict protocols for handling the ﬁlms, scanning the
ﬁlms in multiple orientations, and keeping scan delay times consistent at 24 hr, minimize the uncertainty in the ﬁlm result. Through
internal testing, we have determined the uncertainty in ﬁlm absolute
dose for small targets to be within 2% at all points of the calibration
curve for green channel. Further details on our institutional practice
for SRS/SBRT ﬁlm QA have been published.

5. | CONCLUSION
This study highlights the need for tuning of the radiation target
source size for the AcurosXB dose calculation algorithm in the context of intracranial SRS dose delivery using DCA and VMAT. In particular, we note the differences in optimal source size values for
high-deﬁnition (2.5 mm leaf width) and standard (5 mm leaf width)
MLC with ﬂattening-ﬁlter free delivery. Improper selection of the
source size can affect the accuracy of the shoulder of the high
shoulder for a wide range of intracranial target sizes, and can also
have a drastic effect on the magnitude of the central high-dose
region for very small targets (target volume ≤ 0.30 cc).

This work has been supported in part by a grant from Varian Medical Systems, Palo Alto, CA.
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